Immucell

ICCCNasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$92.003 M

$10.13 +1.81%

Close of 21 Sept 2026

Revenue

$26.5M

#2912 by revenue

Earnings

-$1.04M

Loss-making

Shares outstanding

9,082,197

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#11Myriad GeneticsMYGN$383.6M
#12Insight Molecular DiagnosticsIMDX$131.2M
#13ImmucellICCC$92.0M
#14BiomericaBMRA$11.9M
#15VolitionrxVNRX$7.39M

What if Immucell were worth as much as…

Open the what-if tool →

Gold $30.3T

$3,333,340

Per share 329,056× higher

Bitcoin $1.72T

$189,359.88

Per share 18,693× higher

Nvidia $5.48T

$603,362.60

Per share 59,562× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Immucell are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.